NCT02612415

Brief Summary

A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
121

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Nov 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 23, 2015

Completed
9 days until next milestone

Study Start

First participant enrolled

November 1, 2015

Completed
22 days until next milestone

First Posted

Study publicly available on registry

November 23, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

December 16, 2016

Status Verified

December 1, 2016

Enrollment Period

11 months

First QC Date

October 23, 2015

Last Update Submit

December 15, 2016

Conditions

Outcome Measures

Primary Outcomes (6)

  • Number of eligible patients in Group A (step-up) and Group B (step-down)

    Baseline

  • Number of parents/guardians who refuse prospective or deferred consent

    Through study completion, an average of 24 hours

  • Randomising at least 50% of eligible patients

    Baseline

  • Proportion of patients adherent to the study treatment

    Through study completion, an average of 72 hours

  • Mean COMFORT score

    72 hours

  • Number of parents completing the Parental Stressor Scale: PICU (PSS:PPICU)

    24 hours

Secondary Outcomes (6)

  • Proportion of children randomised to the intervention or control who need intubation (Group A) or re-intubation (Group B)

    72 hours

  • Proportion of children randomised to the intervention or control who fail the assigned treatment and require either crossover or escalation to other forms of ventilation

    72 hours

  • Number of children who experience pre-specified adverse events (pneumothorax, pneumomediastinum, nasal or facial trauma, abdominal distension, nosocomial infection) during the period they are receiving non-invasive respiratory support

    28 days

  • Improvement in oxygenation, partial pressure of carbon dioxide (pCO2) levels, heart rate, respiratory rate, and work of breathing

    24 hours

  • Length of PICU and hospital stay, length of invasive ventilation, length of non-invasive support, ventilator-free days at day 28

    through study completion, an average of 28 days

  • +1 more secondary outcomes

Study Arms (2)

High flow nasal cannula (HFNC)

EXPERIMENTAL

Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC

Device: Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula

Continuous positive airway pressure (CPAP)

ACTIVE COMPARATOR

Continuous positive airway pressure delivered using any interface (hood, mask or prongs)

Device: Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure

Interventions

A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support

High flow nasal cannula (HFNC)

CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support

Continuous positive airway pressure (CPAP)

Eligibility Criteria

Age36 Weeks - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Eligible patients will fall into one of two groups:
  • Group A (Step-up)
  • Age \>36 weeks corrected gestational age and \<16 years, AND
  • Deemed to require non-invasive respiratory support by the treating clinician for an acute illness, AND
  • Satisfies one or more of the following criteria:
  • Hypoxia (oxygen saturation \<92% in fraction of inspired oxygen (FiO2) \>0.40, or equivalent). FiO2 of 0.40 roughly equates to standard unhumidified nasal cannula oxygen delivered at 6 L/min or oxygen delivered via facemask without a rebreather bag at 6-10 L/min.
  • Acute respiratory acidosis (pH \<7.3 with a concomitant pCO2 \>6.5 kPa)
  • Moderate respiratory distress (use of accessory muscles, subcostal and intercostal recession, tachypnoea for age, grunting)
  • Group B (Step-down)
  • Age \>36 weeks corrected for gestation and \<16 years, AND
  • Deemed to require non-invasive respiratory support by the treating clinician after extubation, following a spell of invasive ventilation
  • Either immediately after extubation as a 'planned' procedure, irrespective of clinical condition ('planned') OR
  • Prompted by deterioration in clinical condition within 72 hours after extubation ('rescue'). Clinical parameters to assess the need for NRS in this situation will be similar to point 3 in Group A.

You may not qualify if:

  • Deemed by the treating clinician to require immediate intubation/invasive ventilation due to severe hypoxia, acidosis and/or respiratory distress, upper airway obstruction or recurrent apnoeas
  • Tracheostomy in place
  • Pre-existing air-leak syndrome (pneumothorax/pneumomediastinum)
  • Midfacial/craniofacial anomalies (unrepaired cleft palate, choanal atresia) or had recent craniofacial surgery
  • Agreed limitation of intensive care treatment plan in place ('not for intubation')
  • On domiciliary non-invasive ventilation prior to PICU admission
  • Managed on either HFNC and/or CPAP (or other form of non-invasive ventilation such as BiPAP) in the preceding 24 hours
  • Previously recruited to this study during the same PICU admission
  • Cannot be treated with HFNC
  • Unavailability of appropriate sized nasal prongs
  • Unavailability of HFNC device
  • Cannot be treated with CPAP
  • Unavailability of right size of face mask, prong or other patient interface
  • Unavailability of CPAP device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Barts Health NHS Trust

London, United Kingdom

Location

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom

Location

Imperial College Healthcare NHS Trust

London, United Kingdom

Location

Related Publications (2)

  • Ramnarayan P, Lister P, Dominguez T, Habibi P, Edmonds N, Canter RR, Wulff J, Harrison DA, Mouncey PM, Peters MJ; United Kingdom Paediatric Intensive Care Society Study Group (PICS-SG). FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): a multicentre pilot randomised controlled trial of high-flow nasal cannula therapy versus continuous positive airway pressure in paediatric critical care. Crit Care. 2018 Jun 4;22(1):144. doi: 10.1186/s13054-018-2080-3.

  • Ramnarayan P, Lister P, Dominguez T, Habibi P, Edmonds N, Canter R, Mouncey P, Peters MJ. FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): protocol for a multicentre randomised feasibility trial of non-invasive respiratory support in critically ill children. BMJ Open. 2017 Jun 12;7(6):e016181. doi: 10.1136/bmjopen-2017-016181.

MeSH Terms

Conditions

HypoxiaAcidosis, RespiratoryLymphoma, FollicularDyspnea

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsRespiratory InsufficiencyRespiration DisordersRespiratory Tract DiseasesAcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Padmanabhan Ramnarayan

    Consultant in Paediatric Intensive Care & Retrieval Children's Acute Transport Service (CATS)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2015

First Posted

November 23, 2015

Study Start

November 1, 2015

Primary Completion

October 1, 2016

Study Completion

December 1, 2016

Last Updated

December 16, 2016

Record last verified: 2016-12

Locations